This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Von Willebrand disease폰빌레브란트병

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D68.0 (von Willebrand disease) | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsVon Willebrand disease (vWD), vascular haemophilia, angiohaemophilia, constitutional thrombopathy, pseudohemophilia A, von Willebrand factor deficiency
C. Adult onsetPossibility of first manifestation in adulthood: very likely — vWD is the most common hereditary bleeding disorder; about 1% of the entire population carries a gene variant, but far fewer patients actually experience clinical symptoms; type 1 in particular (70-80% of the total) is one of the hematologic diseases most often first diagnosed in adulthood, with mild symptoms, on the occasion of pregnancy, childbirth, surgery, or tooth extraction; both men and women are affected, so there are many adult cases first discovered in women because of heavy menstrual bleeding.
1. History1926 first description by Erik von Willebrand → cloning of the VWF gene → current classification system
2. CausesVWF gene (12p13.3) variants: type 1 (quantitative deficiency), type 2 (qualitative defect), type 3 (complete deficiency)
3. GeneticsVWF 12p13.3, 178kb, 52 exons; autosomal dominant (types 1, 2) / recessive (types 2N, 3)
4. EpidemiologyGene variant carrier rate ~1%; symptomatic prevalence about 125 per million; most common hereditary bleeding disorder
5. PathophysiologyImpaired vWF binding to platelet GPIbα → poor primary hemostasis; reduced FVIII carrier function
6. SymptomsEpistaxis, gum bleeding, bruising; heavy menstrual bleeding in women; type 3: spontaneous muscle and joint bleeding
7. SignsProlonged bleeding time, decreased vWF:Ag, decreased vWF:RCo, decreased FVIII:C (types 3 and 2N)
8. ScreeningBleeding score (BAT), PFA-100/200, APTT; vWF:Ag, vWF:RCo, FVIII:C
9. DiagnosisvWF multimer electrophoresis, RIPA, vWF:FVIII binding (type 2N), VWF NGS
10. TreatmentDDAVP (type 1), vWF concentrates (types 2B, 3), tranexamic acid, oral contraceptives
11. PrognosisNormal life expectancy in type 1; joint damage possible in type 3 but managed with treatment
12. PreventionGenetic counseling, carrier identification, DDAVP response test, planning before surgery and delivery
13. References10 or more international standard references

1. History

The history of von Willebrand disease begins when the Finnish internist Erik Adolf von Willebrand (1870-1949) examined a 5-year-old girl named Hjördis from the Åland Islands of Finland in 1924. Hjördis and her family members had recurrent epistaxis, gum bleeding, and mucocutaneous bleeding without surgery or severe trauma, which clinically appeared similar to hemophilia, already known at the time. However, unlike hemophilia, women in this family were affected equally, the platelet count was normal, and the prothrombin time (PT) and coagulation tests were also normal. The key finding that von Willebrand particularly noted was that the bleeding time (Duke's test) was markedly prolonged. A prolonged bleeding time without a decrease in platelet count was a finding that strongly suggested an abnormality of platelet function or vessel-platelet interaction.

In 1926, von Willebrand first reported this disease under the name Hereditäre Pseudohämophilie (hereditary pseudohemophilia) in the Finnish Swedish-language medical journal Finska Läkaresällskapets Handlingar. The name 'pseudohemophilia' he chose reflected that it is clinically similar to hemophilia but differs in test pattern. At the time, von Willebrand inferred that the abnormality of this disease lay in the vessel wall or the vessel-platelet boundary rather than in platelets or coagulation factors, and some literature also called it 'vascular hemophilia (vaskuläre Hämophilie, vascular hemophilia)'. Unfortunately, the first patient, Hjördis, died at the age of 13 in 1926 from bleeding that occurred during heavy menstruation.

In the 1950s, researchers began to understand the mechanism of this disease more precisely. In 1953, Erik Jorpes and Birger Blombäck of Sweden published research results suggesting that a separate factor binding factor VIII (FVIII) exists in plasma. This research later foreshadowed the fact that vWF functions as a carrier protein of FVIII. In 1957, von Willebrand himself also published detailed follow-up results of this disease, reporting that in the interim four people in the Åland Islands family had died of this disease.

1971 was a watershed year for vWD research. Zimmermann, Ratnoff, and Powell developed an immunological method (using anti-vWF antibody) to independently measure vWF antigen in plasma, making it possible to measure vWF antigen (vWF:Ag) and FVIII coagulant activity (FVIII:C) separately. With the development of this method, classical hemophilia A (decreased FVIII:C, normal vWF:Ag) and vWD (decreased vWF:Ag or vWF dysfunction) could be clearly distinguished at the laboratory level, and research on the subtype classification of vWD began in earnest.

In the 1980s, understanding of the structure and function of the vWF protein advanced greatly. It was revealed that vWF forms a multimer structure of monomers linked by disulfide bonds, and that high-molecular-weight multimers (HMW multimers) play the most important role in platelet adhesion. On this basis, a classification system for type 2 subtypes (2A, 2B, 2C, 2D, 2M, 2N, etc.) began to be established. In particular, a unique clinical phenotype was identified in which type 2B is accompanied by thrombocytopenia together with decreased HMW multimers. In 1982, DDAVP (desmopressin) was shown to be effective in vWD type 1 patients in releasing vWF stored within endothelial cells and transiently raising vWF levels, a breakthrough in the treatment of mild vWD.

In 1986, the research teams of Bonthron, Orr, Sadler, and others succeeded in cloning the VWF gene. It was revealed that the VWF gene is located on chromosome 12p13.3, consists of 178kb and 52 exons, and encodes a precursor protein of 2,813 amino acids. Subsequently, the existence of a VWF pseudogene on chromosome 22 was also confirmed, making it important to distinguish it in genetic analysis. In 1989, Sadler et al. standardized the ristocetin cofactor activity (vWF:RCo) assay, establishing a methodology that can quantify the functional defect of vWF.

In 1994 and 2006, the vWF Subcommittee (SSC) of the ISTH (International Society on Thrombosis and Haemostasis) standardized and internationally announced the current classification system of type 1/type 2 (2A, 2B, 2M, 2N)/type 3. This classification is the standard still used today and clearly distinguishes quantitative deficiency (types 1 and 3) from qualitative defect (type 2). In 1994, type 2N (Normandy type) was recognized as an official subtype; it is characterized in that FVIII:C is low owing to a variant in the FVIII binding site of vWF and may be confused with hemophilia A, but it is inherited in an autosomal recessive manner without sex distinction.

In Korea, since the 2000s, National Health Insurance coverage and rare disease Special Copayment Reduction (V009) have applied, and registered patients receive the benefit of a 10% copayment rate for 5 years. In 2021, the US FDA approved vonicog alfa (trade name Vonvendi), the first-ever recombinant vWF concentrate, adding a new option to treatment that had depended on plasma-derived products. DDAVP nasal spray (Stimate) is also actively used in outpatient treatment of patients with mild vWD, and precision genetic diagnosis through gene panel testing (NGS) has been standardized and plays an important role in subtype classification and treatment planning.


2. Causes

Von Willebrand disease is a hereditary bleeding disorder caused by various variants of the VWF gene (chromosome 12p13.3). The VWF gene consists of 52 exons over a length of 178kb, and more than 1,000 VWF variants have been registered to date in databases (ISTH VWF variant database). The type and severity of vWD are determined by the type and location of the variant.

Type 1 is characterized by partial quantitative deficiency of vWF (vWF:Ag 30-50%) and mainly arises from heterozygous variants. Variant types are diverse, including nonsense, splicing, and missense variants, and these cause decreased vWF synthesis, impaired storage in endothelial cells (Weibel-Palade bodies), or decreased extracellular secretion. Type 1 shows very large variability in expressivity, and vWF levels can fluctuate with external factors such as blood group O (vWF:Ag about 25% lower), pregnancy, age, and inflammation.

Type 2 is a qualitative defect of the vWF protein, mainly caused by missense variants in specific functional domains. In type 2A, A2 domain variants cause impaired formation of high-molecular-weight multimers or excessive degradation by ADAMTS13. In type 2B, A1 domain variants abnormally increase affinity for platelet GPIbα, so platelets are excessively consumed, and thrombocytopenia may accompany. In type 2M, A1 or A3 domain variants reduce platelet or collagen binding capacity although the multimer structure is normal. In type 2N (Normandy type), variants of the D'-D3 domain abolish FVIII binding capacity so that FVIII:C becomes markedly low, and an autosomal recessive inheritance pattern is shown.

Type 3 is a state in which null variants occur in both alleles of the VWF gene (homozygous or compound heterozygous) and vWF is almost completely deficient (vWF:Ag <1%). Deletions, nonsense variants, and frameshift variants predominate, and a severe bleeding phenotype is shown. FVIII is also degraded rapidly because it lacks protection by vWF, so FVIII:C is also markedly low.

Acquired vWD is a separate category and can occur with lymphoproliferative disorders, shear stress due to aortic valve stenosis, hypothyroidism, autoimmune diseases, and so on, but its mechanism of occurrence differs from that of hereditary vWD.


3. Genetics

The VWF gene is located on chromosome 12p13.3 and consists of a total length of 178kb and 52 exons. The precursor protein (pre-pro-VWF) consists of 2,813 amino acids and, through cleavage of the signal peptide and processing of the pro-peptide, becomes the mature vWF monomer (2,050 amino acids, about 250 kDa). Mature vWF monomers are linked by disulfide bonds to form high-molecular-weight multimers, and the larger the multimer, the stronger its ability to promote platelet adhesion.

The domain structure of the vWF protein is arranged in the order D1-D2 (pro-peptide)-D'-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK, and each domain interacts with specific binding partners. The D'-D3 domain is essential for FVIII binding, and the A1 domain binds platelet GPIbα, collagen, and ristocetin. The A2 domain contains the cleavage site for ADAMTS13 (VWF-73 sequence), and the A3 domain binds collagen of the subendothelial matrix (especially types I and III). The C1/C2 domains bind platelet GPIIb-IIIa (integrin αIIbβ3) and promote platelet aggregation.

The mode of inheritance differs by type. Type 1 and most type 2 show autosomal dominant inheritance, and bleeding symptoms can appear even in heterozygous carriers. Types 2N and 3 show autosomal recessive inheritance, and a clinically marked phenotype appears when homozygous or compound heterozygous. Variability in expressivity is very large, and the degree of bleeding symptoms can differ even within a family carrying the same variant. External factors such as blood group O (vWF:Ag decreased by about 25%), hormones (estrogen → increased vWF), age (aging → increased vWF), and acute-phase response (infection, inflammation → increased vWF) affect vWF levels and symptom expression.

As a point of caution, a VWF pseudogene (VWFP) exists on chromosome 22 and shows about 97% or greater homology with VWF exons 23-34. In molecular genetic testing, confusion with the pseudogene can produce false-positive results, so it is essential to use long-range PCR or specific primers. Recently, NGS (next-generation sequencing) panels covering the entire VWF gene (exons, intron boundaries, promoter, UTR) have been used in clinical diagnosis.


4. Epidemiology

Von Willebrand disease is the most common hereditary bleeding disorder worldwide. The carrier rate of VWF gene variants in the general population is estimated at about 1% (1 in 100), but the number of patients who actually develop clinical symptoms and are diagnosed is about 125 per million, so the symptomatic prevalence is much lower. This difference is because in type 1 the symptoms are mild and often go undiagnosed. In particular, when epistaxis, gum bleeding, or bruising is mild, these are symptoms commonly experienced by the general population, so diagnosis is often delayed or missed.

The sex distribution is theoretically equal between men and women (autosomal inheritance). However, clinically, women tend to be diagnosed more often and visit medical institutions more often because of heavy menstrual bleeding (menorrhagia). This is not because symptoms are more pronounced in women, but because the physiological hemostatic challenge of menstruation occurs periodically. Conversely, even with a similar degree of vWD, men have fewer opportunities for diagnosis, so the diagnosis rate may be lower.

By type, type 1 accounts for 70-80% of the total, type 2 about 15-20% (of which type 2A is the most common, followed by 2B, 2M, and 2N), and type 3 is rare at about 1-3 per million. Because type 3 is autosomal recessive, its prevalence is reported to be relatively high in regions with a high frequency of consanguineous marriage (some regions such as Iran and India). In Korea, the number of registered patients is identified from Health Insurance Review & Assessment Service data, but including undiagnosed mild patients, the actual prevalence is estimated to be much higher than the number of registered patients.

By age, first diagnosis in adulthood is common in type 1, in which symptoms are mild. Symptoms are slight in childhood and go unrecognized, and not a few adult women are tested only after experiencing massive bleeding after a first delivery or more bleeding than expected after a first surgery. Some are also first discovered with the chief complaint of poor hemostasis after tooth extraction.


5. Pathophysiology

Von Willebrand factor (vWF) is a multimeric glycoprotein produced by vascular endothelial cells (the main cells of synthesis and storage) and platelets (stored in α-granules). Within endothelial cells, vWF is stored in Weibel-Palade bodies and secreted in response to stimuli such as vascular injury, DDAVP, thrombin, and histamine. Secreted vWF binds to collagen of the subendothelial matrix (mainly types I, III, and VI) and forms a platelet-capturing matrix.

vWF has two key physiological functions. First, mediation of platelet adhesion: under high shear flow, vWF binds to collagen, after which the A1 domain is exposed and binds platelet surface GPIbα (GP Ib-IX-V complex). Through this, platelets are captured at the site of vascular injury and subsequently adhere stably through GPIIb-IIIa. In vWF deficiency or dysfunction, this primary hemostatic response becomes insufficient. In particular, because high-molecular-weight multimers have the greatest platelet adhesion capacity, loss of high-molecular-weight multimers in types 2A and 2B greatly reduces platelet adhesion.

Second, stabilization and transport of FVIII: vWF binds non-covalently to FVIII in plasma and protects FVIII from proteolysis (mainly premature inactivation by activated protein C, FXa, etc.). The half-life of FVIII bound to vWF is maintained at about 12 hours or more, but when vWF is deficient, FVIII is rapidly cleared from plasma. As a result, mildly decreased FVIII:C appears in type 1 and severely decreased FVIII:C (below 10-20 IU/dL) in type 3, so secondary hemostasis (coagulation pathway) is also affected.

In type 2B, gain-of-function variants of the A1 domain pathologically increase vWF-GPIbα binding affinity. As a result, platelets are abnormally captured even without vascular injury, platelets are consumed, and high-molecular-weight multimers are also lost. This produces a paradoxical situation in which thrombocytopenia and a bleeding tendency appear at the same time. When DDAVP is given, additional secretion of vWF actually worsens the thrombocytopenia, so DDAVP is contraindicated in type 2B.

ADAMTS13 is a metalloprotease in plasma that cleaves the Tyr1605-Met1606 bond of the vWF A2 domain (VWF-73 sequence) to degrade ultra-large multimers (ultra-large, UL-vWF) and regulate the size of vWF multimers in the circulation. When ADAMTS13 activity is deficient, UL-vWF accumulates and thrombotic thrombocytopenic purpura (TTP) develops. In vWD there is no ADAMTS13 deficiency, but in some cases of type 2A, A2 domain variants cause excessive cleavage by ADAMTS13 and loss of high-molecular-weight multimers.


6. Symptoms

The main symptom of von Willebrand disease is mucocutaneous bleeding. Epistaxis (nosebleed) is one of the most common symptoms, occurring easily spontaneously or with minor trauma and characterized by poor hemostasis. Gingival bleeding, skin bruising, and mucosal bleeding (mouth, gastrointestinal tract, genitourinary tract) are also common. In type 1 these symptoms are mild and intermittent, so they are easily mistaken for normal variation.

In women, heavy menstrual bleeding (menorrhagia) is the most common and sometimes the only symptom. Excessive bleeding from the onset of menstruation, passage of clots, and prolonged menstruation are characteristic, and anemia develops in severe cases. For this reason, it is often first discovered in obstetrics-gynecology or internal medicine. During pregnancy vWF rises physiologically (third trimester: up to 3-5 times), so symptoms transiently improve, but immediately after delivery vWF falls sharply and the risk of postpartum hemorrhage increases greatly. This must be considered when establishing a delivery plan.

Delayed hemostasis or excessive bleeding after surgery, tooth extraction, and trauma is also a common symptom. In particular, after tonsillectomy, adenoidectomy, and dental extraction, hemostasis may be poor or rebleeding may occur a few days later. Gastrointestinal bleeding (digestive tract bleeding) can occur in elderly patients together with accompanying angioectasia.

Symptoms differ by type 2 subtype. Types 2A and 2B have mucosal bleeding of moderate or greater severity due to loss of high-molecular-weight multimers. Type 2B may be accompanied by thrombocytopenia. In type 2M, mucosal bleeding is the main symptom. In type 2N, owing to decreased FVIII:C, joint bleeding (hemarthrosis) or muscle bleeding may occur similarly to hemophilia A, and because men and women are affected equally, differentiation from X-linked hemophilia A is important.

Type 3 is the most severe phenotype, with vWF almost completely deficient and FVIII:C also markedly low, causing severe bleeding similar to hemophilia A. Spontaneous joint bleeding, deep muscle bleeding, and recurrent arthropathy (hemophilic arthropathy) may occur, and life-threatening central nervous system bleeding may also occur. In type 3, formation of antibodies (alloantibodies) against plasma-derived vWF concentrates may rarely occur and can complicate treatment.


7. Signs

In von Willebrand disease, physical examination findings are often nonspecific, but laboratory findings are key to diagnosis. Physical examination may show signs of mucosal bleeding (nasal mucosal vascular dilatation, gum bleeding), skin bruising, and hematomas (joint or muscle, mainly type 3).

Bleeding time is the most classical screening test, but it has now been replaced at most institutions by PFA-100/PFA-200 (platelet function analyzer) because of large inter-operator variability and difficulty in standardization. The PFA-100/200 measures the time (closure time) for platelets to occlude a collagen-ADP or collagen-epinephrine membrane under high-shear conditions, and closure time is prolonged in vWF deficiency.

On blood coagulation tests, APTT may be prolonged in type 3 or type 2N when FVIII:C is low, but may be normal in mild type 1 and type 2. The platelet count is mostly normal, but in type 2B mild or moderate thrombocytopenia may accompany. PT is generally normal.

Specific test findings include decreased vWF:Ag (vWF antigen) (types 1 and 3), decreased vWF:RCo (ristocetin cofactor activity) or vWF:GPIbM (reflecting functional vWF deficiency), and decreased FVIII:C (especially types 2N and 3). A vWF:RCo/vWF:Ag ratio below 0.7 suggests a qualitative defect (type 2). On vWF multimer electrophoresis (multimer analysis), absence of high-molecular-weight multimers is found in types 2A and 2B, and in types 1, 2M, 2N, and 3 the multimer distribution is normal (almost absent in type 3) or overall decreased. On RIPA (ristocetin-induced platelet aggregation), type 2B is characterized by an abnormal aggregation response to low-concentration (0.5-0.7 mg/mL) ristocetin. Type 2N shows decreased binding capacity on the vWF:FVIII binding assay, allowing differentiation from hemophilia A.


8. Screening

Screening for von Willebrand disease begins with systematic evaluation of bleeding history. The Bleeding Assessment Tool (BAT) standardized by the International Society on Thrombosis and Haemostasis (ISTH) or the MCMDM-1 (Molecular and Clinical Markers for the Diagnosis and Management of Type 1 vWD) questionnaire is used. These tools score various bleeding history items such as epistaxis, gum bleeding, bruising, heavy menstrual bleeding, bleeding after surgery, and bleeding after tooth extraction, and help decide whether to continue testing. Further detailed testing is recommended if the BAT score is ≥3 in men, ≥5 in women, and ≥2 in children.

For laboratory screening, PFA-100/200 (platelet function analyzer) is performed first. Prolonged closure time suggests vWF dysfunction or platelet dysfunction. APTT reflects whether FVIII:C is decreased; it may be normal in types 1 and 2 but is prolonged in types 2N and 3. The platelet count may be decreased in type 2B. If an abnormality is found in these 3 screening tests, one proceeds to specific confirmatory tests.

An important precaution is that in blood group O, vWF:Ag is about 25% lower than in other people, so blood group must be considered at diagnosis. In addition, vWF rises physiologically during acute inflammatory response or pregnancy and false negatives may occur, so repeat testing at a stable time (not in the acute phase) is recommended in suspicious cases. In women taking estrogen-containing contraceptives, vWF may also be elevated, so testing after discontinuing them should be considered.


9. Diagnosis

Definitive diagnosis of von Willebrand disease is made by a combination of several tests. The specific confirmatory tests are as follows.

vWF:Ag (vWF antigen): Measured by ELISA or immunoturbidimetric assay (LIA). Decreased in types 1 and 3, and variable in type 2, from normal to decreased. Reference range: 50-150 IU/dL. A value below the lower limit of normal (50 IU/dL) plus a clinical bleeding history supports the possibility of vWD. In some studies, 30-50 IU/dL is classified as 'low VWF', and discussion is ongoing about whether it should be regarded as borderline with vWD type 1.

vWF:RCo (ristocetin cofactor activity) or vWF:GPIbM (GPIbα binding activity): Evaluates the platelet binding function of vWF. A vWF:RCo/vWF:Ag ratio <0.7 suggests type 2. vWF:GPIbM is a recently introduced standardized method with excellent reproducibility.

FVIII:C (FVIII coagulant activity): Markedly decreased in types 2N and 3. A normal FVIII:C/vWF:Ag ratio (about 1) means that FVIII binding function is preserved relative to vWF.

vWF multimer electrophoresis (multimer gel electrophoresis): Visualizes the vWF multimer distribution by SDS-agarose gel electrophoresis. Types 2A and 2B: loss of high-molecular-weight multimers. Types 2M, 2N, and 1: normal distribution. Type 3: loss of all multimers. In type 2B, an abnormal internal band pattern of intermediate-molecular-weight multimers (abnormal satellite bands) is characteristic.

RIPA (ristocetin-induced platelet aggregation): The response to low-concentration (0.5-0.7 mg/mL) ristocetin is checked using the patient's platelets. In type 2B, abnormal aggregation at low-concentration ristocetin (normal: no response) is characteristic and is the key finding for diagnosing type 2B.

vWF:FVIII binding assay (vWF:FVIIIB): Confirms type 2N. Evaluates whether FVIII binding capacity is lost owing to D'-D3 domain variants. Essential for differentiating hemophilia A (FVIII gene variant) from type 2N (VWF gene variant), and judged comprehensively together with family history and mode of inheritance (autosomal recessive vs. X-linked).

VWF molecular genetic testing (NGS): Analysis of all 52 exons of the VWF gene + promoter + UTR + pseudogene discrimination. Used when the diagnosis is uncertain or subtype classification is difficult, for family screening, genetic counseling, and carrier diagnosis. To avoid confusion with the pseudogene (chromosome 22), use of long-range PCR or a specific method is essential.


10. Treatment

The treatment principles for von Willebrand disease are prevention and control of bleeding, and securing an appropriate vWF level before surgery and invasive procedures. Treatment selection is individualized according to type, severity, and clinical situation.

DDAVP (desmopressin) is the first-line choice for treatment of type 1 vWD. Desmopressin is a synthetic vasopressin (AVP) analog that stimulates V2 receptors on endothelial cells to release vWF stored in Weibel-Palade bodies into plasma. Within 30 minutes after administration, vWF:Ag and FVIII:C rise 2-5 times, and about 80% of patients with type 1 or 2 respond well. It can be given by intravenous injection (IV, 0.3 mcg/kg, 20-30-minute infusion), subcutaneous injection, or high-concentration nasal spray (Stimate, 150 mcg/spray, one spray in each nostril in adults). Repeat doses should be spaced 48-72 hours or more apart, and with frequent administration tachyphylaxis (decreased response due to depletion of stored vWF) can occur. Fluid retention and dilutional hyponatremia can occur as side effects, so fluid intake is restricted during administration and caution is needed in children and the elderly. Contraindicated in type 2B (risk of worsening thrombocytopenia), and ineffective in type 3 because there is no stored vWF.

vWF concentrates are used in patients who do not respond to DDAVP, in types 2B and 3, and in moderate to severe type 2. Plasma-derived products include Humate-P (contains vWF + FVIII), Wilate (vWF + FVIII, high purity), Alphanate, and Beriate, and each product has a different vWF:RCo/FVIII ratio. Vonicog alfa (Vonvendi), a recombinant vWF product approved by the FDA in 2021, is produced by recombinant technology and has no risk of virus transmission and does not contain FVIII (used together with recombinant FVIII when needed). The dose is calculated on the basis of vWF:RCo, and target levels differ by situation: 80-100 IU/dL before surgery, 50-60 IU/dL for hemostasis prophylaxis, and 30-50 IU/dL or more during prophylaxis in type 3.

Tranexamic acid is an antifibrinolytic and is widely used as adjunctive treatment of mucosal bleeding such as epistaxis, gum bleeding, heavy menstrual bleeding, and bleeding after tooth extraction. It can be given orally or intravenously, alone or together with DDAVP/vWF concentrates. In genitourinary bleeding, use with caution because of the risk of upper urinary tract obstruction.

Oral contraceptive pills (OCP) are effective for controlling heavy menstrual bleeding in women, and the estrogen component can also be expected to have the additional effect of increasing vWF synthesis. The levonorgestrel intrauterine device (Mirena IUD) is also used for controlling heavy menstrual bleeding.

Pregnancy and delivery management: During pregnancy vWF rises physiologically but falls sharply after delivery, so the vWF:RCo target should be maintained at 50 IU/dL or more at delivery (100 IU/dL or more for cesarean section). Monitoring of vWF levels until 4 weeks postpartum and, when needed, administration of DDAVP or vWF concentrates are recommended. In type 3 patients, formation of antibodies (alloantibodies) against plasma-derived vWF products is monitored.


11. Prognosis

Type 1 patients respond well to treatment, and with appropriate management life expectancy is the same as the general population. Type 1 patients with mild symptoms who respond well to DDAVP have no major limitation in daily life except in hemostatic stress situations such as surgery or delivery. However, owing to random fluctuations in vWF levels (infection, stress, age-related rise, etc.), symptoms in adults may improve or worsen.

The prognosis of type 2 differs by subtype. Types 2A and 2B have a bleeding tendency of moderate or greater severity but can be treated appropriately with vWF concentrates. If thrombocytopenia persists in type 2B, additional management is needed. Type 2N has a good prognosis if FVIII:C is corrected with DDAVP or vWF-containing products, but if misdiagnosed as hemophilia A and treated with recombinant FVIII alone, the effect is insufficient (the FVIII half-life remains short owing to the absence of vWF).

Type 3 is the most severe phenotype, and without treatment serious complications such as arthropathy, muscle atrophy, and central nervous system bleeding can occur. Regular prophylaxis can prevent joint damage and maintain quality of life. Although rare, when antibodies (alloantibodies) form against plasma-derived vWF products, immune reactions (including anaphylaxis) can occur and complicate treatment. In this case, a recombinant vWF product or immune tolerance induction is considered.

Overall, with appropriate diagnosis and treatment planning (preoperative preparation, delivery planning, prophylaxis), most vWD patients can maintain a near-normal quality of life. The factors with the greatest impact on quality of life are repeated hospital treatment, chronic joint pain (type 3), persistent heavy menstrual bleeding, and psychological burden.


12. Prevention

Because von Willebrand disease is a hereditary disease, primary prevention is achieved through genetic counseling. Type 1 and most type 2 are autosomal dominant, so a patient's child has a 50% chance of inheriting the variant. Types 2N and 3 are autosomal recessive, so when both parents are carriers, there is a 25% chance that a child will be affected. Molecular genetic testing is recommended to identify carriers within the family, and in families with severe disease (type 3), fetal diagnosis is also possible through prenatal diagnosis (chorionic villus testing or amniotic fluid testing).

The most important secondary prevention is advance preparation for situations that provoke bleeding. Before surgery, dental extraction, and invasive procedures, a consultation with a hematologist is essential, and the vWF/FVIII level must be raised above the target before proceeding with the procedure. In type 1 patients, it is important to perform a DDAVP response test (test dose) before the procedure to confirm whether and to what degree there is a response. Drugs that inhibit platelet function, such as aspirin and NSAIDs, should be avoided as far as possible, and when unavoidable should be used after correcting the vWF level.

Menstrual management is important in female patients. Controlling heavy menstrual bleeding with oral contraceptives, tranexamic acid, the levonorgestrel IUD, and so on contributes greatly to preventing anemia and improving quality of life. Pregnancy and delivery planning must be done in consultation with hematology and obstetrics-gynecology, with regular monitoring of vWF levels from the second trimester and a plan for bleeding prevention at delivery and until 4 weeks postpartum.

Patients with type 3 and severe type 2 can reduce the frequency of spontaneous bleeding and prevent joint damage through prophylaxis — regular administration of vWF concentrates. The key to preventive management is to build, through patient education, emergency bleeding management methods, possession of emergency medications (tranexamic acid, DDAVP nasal spray), and a system of close linkage with a specialized hematology center.


13. References

  1. von Willebrand EA. Hereditär pseudohemofili. Finska Läkaresällsk Handl. 1926;68:87-112.
  2. Sadler JE, Budde U, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103-2114.
  3. Leebeek FW, Eikenboom JC. Von Willebrand's disease. N Engl J Med. 2016;375(21):2067-2080.
  4. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines. Haemophilia. 2008;14(2):171-232.
  5. Federici AB, Mannucci PM, Castaman G, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B. J Thromb Haemost. 2009;7(4):572-579.
  6. Srivastava A, et al. WFH Guidelines for the Management of Haemophilia, 3rd ed. Haemophilia. 2020;26(S6):1-158.
  7. James AH, Manco-Johnson MJ, Yawn BP, Dietrich JE, Nichols WL. Von Willebrand disease: key points from the 2008 National Heart, Lung, and Blood Institute guidelines. Obstet Gynecol. 2009;114(3):674-678.
  8. Ruggeri ZM, Zimmermann TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood. 1981;57(6):1140-1143.
  9. Castaman G, Goodeve A, Eikenboom J; European Group on von Willebrand Disease. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica. 2013;98(5):667-674.
  10. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med. 2004;351(7):683-694.